Insulin use and persistence in patients with type 2 diabetes adding mealtime insulin to a basal regimen: A retrospective database analysis

BMC Endocrine Disorders

Volumn 11, Issue , 2011, Pages

  Bonafede, Machaon M ^a   Kalsekar, Anupama ^b,c   Pawaskar, Manjiri ^c   Ruiz, Kimberly M ^d   Torres, Amelito M ^d,e   Kelly, Karen R ^c   Curkendall, Suellen M ^d  

^a Thomson Reuters Inc   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c ELI LILLY AND COMPANY   (United States)

^d THOMSON REUTERS   (United Kingdom)

^e GE HEALTHCARE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMALOG MIX 50 50; HUMALOG MIX 75 25; HUMAN INSULIN; INSULIN; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; LISPRO PFC; NEUTRAL INSULIN; NOVOLIN 70 30; NOVOLOG MIX 70 30; RECOMBINANT HUMAN INSULIN; RELION NOVOLIN 70 30; RELION PLUS NOVOLIN N; RELION PLUS NOVOLIN R; UNCLASSIFIED DRUG;

ADULT; AGED; AGING; ARTICLE; CLINICAL ASSESSMENT; COMORBIDITY; CONTROLLED STUDY; DATA BASE; DIABETIC PATIENT; DRUG COST; DRUG EFFICACY; FEMALE; HEALTH CARE PLANNING; HUMAN; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MEAL; MENTAL DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; POLYPHARMACY; RETROSPECTIVE STUDY; RISK FACTOR; SYRINGE; TREATMENT DURATION;

EID: 78751703602     PISSN: None     EISSN: 14726823     Source Type: Journal    
DOI: 10.1186/1472-6823-11-3     Document Type: Article

References (18)

1. American Diabetes Association Standards of medical care in diabetes--2008. Diabetes Care 2008, 31(suppl. 1):S12-S54. American Diabetes Association.
2. Meece J. Dispelling myths and removing barriers about insulin in type 2 diabetes. Diabetes Educ 2006, 32(1 Suppl):9S-18S. 10.1177/0145721705285638, 16439485.
3. Korytkowski M. When oral agents fail: Practical barriers to starting insulin. Int J Obes Relat Metab Disord 2002, 26:S18-24. 10.1038/sj.ijo.0802173, 12174319.
4. Riddle MC. The underuse of insulin therapy in North America. Diabetes Metab Res Rev 2002, 18(3 Suppl):S42-S49. 10.1002/dmrr.277, 12324985.
5. Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care 2004, 27:1218-1224. 10.2337/diacare.27.5.1218, 15111553.
6. Catalan VS, Couture JA, Lelorier J. Predictors of persistence of use with the novel antidiabetic agent acarbose. Arch Int Med 2001, 161:1106-1112.
7. Dailey G, Kim MS, Lian JF. Patient compliance and persistence with antihyperglycemic drug regimens: evaluation of a Medicaid patients population with type 2 diabetes mellitus. Clin Ther 2001, 23:1311-1320. 10.1016/S0149-2918(01)80110-7, 11558867.
8. Dezii CM, Kawabata H, Tran M. Effects of once-daily and twice-daily dosing on adherence with prescribed glizipide oral therapy for type 2 diabetes. South Med J 2002, 95:68-71.
9. Paes AH, Bakker A, Soe-Agnie CJ. Impact of dosage frequency on patient compliance. Diabetes Care 1997, 20(10):15121517.
10. Odegard PS, Capoccia K. Medication taking and diabetes: A systematic review of the literature. Diabetes Educ 2007, 33:1014-1029. 10.1177/0145721707308407, 18057270.
11. Bonafede M, Kalsekar A, Pawaskar M, Ruiz KM, Torres AM, Kelly KR, Curkendall SM. A retrospective database analysis of insulin use patterns in insulin-naïve patients with type 2 diabetes initiating basal insulin or mixtures. Pat Pref Adh 2010, 4:147-156.
12. Peterson AM, Nau DP, Cramer JA, Benner J, Gwadry-Sridhar F, Nichol M. A Checklist for Medication Compliance and Persistence Studies Using Retrospective Databases. Value in Health 2007, 10(1):3-12. 10.1111/j.1524-4733.2006.00139.x, 17261111.
13. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992, 45:613-19. 10.1016/0895-4356(92)90133-8, 1607900.
14. Sikka R, Xia F, Aubert RE. Estimating Medication Persistency Using Administrative Claims Data. Am J Manag Care 2005, 11:449-457.
15. Pawaskar MD, Camacho FT, Anderson RT, Cobden D, Joshi AV, Balkrishnan R. Health care costs and medication adherence associated with initiation of insulin pen therapy in medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis. Clin Ther 2007, 29:1294-305.
16. Fabunmi R, Nielsen LL, Quimbo R, Schroeder B, Misurski D, Wintle M, Wade R. Patient characteristics, drug adherence patterns, and hypoglycemia costs for patients with type 2 diabetes mellitus newly initiated on exenatide or insulin glargine. Curr Med Res Opin 2009, 25(3):777-786. 10.1185/03007990802715199, 19203299.
17. Mayfield JA, White RD. Insulin therapy for type 2 diabetes: Rescue, augmentation, and replacement of beta-cell function. Amer Fam Phys 2004, 70(3):489-500.
18. Yki-Järvinen H. Combination therapies with insulin in type 2 diabetes. Diabetes Care 2001, 24:758-67.